Cavalry Biosciences
PrivateLast Round
Series B
Jun 8, 2026
Total Funding Raised
$40.27M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Cavalry Biosciences is a biotechnology company developing therapeutic drugs to treat rare and chronic diseases by engineering tissue-selective growth factors and cytokines.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cavalry Biosciences Comparables
Compare Cavalry Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Silver Creek Pharmaceuticals | 76% | |
| miRecule, Inc. | 76% | |
| Dyne Therapeutics | 67% |
Cavalry Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 8, 2026 | ||||
| Grant | Sep 22, 2023 | ||||
| Series A | Nov 1, 2021 |
Cavalry Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Lilly Ventures | Series A |
| NIH RADx | Grant |
| Mission BioCapital | Series A |
| Venrock | Series A |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Grew 21% QoQ from 14 to 17 employees.
- Jun 8, 2026
Raised $75M in Series B funding.
Cavalry Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Cavalry Biosciences's valuation, stock price, and market status.
Is Cavalry Biosciences a public or private company?
Cavalry Biosciences is a private company.
What is the current stock price of Cavalry Biosciences?
Cavalry Biosciences is a private company, so its shares have no public market price. Caplight tracks Cavalry Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cavalry Biosciences worth (valuation)?
Valuation information for Cavalry Biosciences is not publicly available.
Can I buy Cavalry Biosciences stock?
Cavalry Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cavalry Biosciences's last funding round?
Cavalry Biosciences's most recent funding round was Series B on June 8, 2026.
Who are the main investors in Cavalry Biosciences?
Key investors in Cavalry Biosciences include Lilly Ventures, NIH RADx, Mission BioCapital, Venrock, Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Will Cavalry Biosciences IPO soon?
No public IPO plans have been announced for Cavalry Biosciences.
How can I track Cavalry Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Cavalry Biosciences's shares on secondary markets.